Gastrointestinal Articles Flashcards
(50 cards)
Videofluoroscopic swallow study features of lower esophageal sphincter achalasia-like syndrome in dogs - Grobman 2019 (JVIM)
Retrospective (19 LES-AS, 20 controls). 19 LES-AS/130 dogs (14.6%). 14/19 (73.7%) had ME. 68.4% had fluid line. 63.2% had “beak sign.” 8/19 (42%) acontractile esophagus, 42% hypomotile, 16% hypermotile. LES-AS can be IDed on free-feeding VFSS.
Mechanical dilation, botulinum toxin A injection, and surgical myotomy with fundoplication for treatment of LES-AS in dogs - Grobman 2019 (JVIM)
Retrospective (14 client-owned dogs with LES-AS - dogs with + response to botox candidates for surgery). 100% dogs improved w/in 21 days of BTA - BW increased 20.4%, BCS 3 –> 5, regurgitation frequency dec. 80%. Duration of benefit ~ 40 days. Despite clinical improvement, ME/dysmotility persisted in 14/14 dogs. 6 underwent myotomy/fundoplication + maintained improvement. Significant temporary improvement after mechanical dilation + BTA. Myotomy + fundoplication provides lasting benefit despite persistent ME.
Canine perianal fistulas: clinical presentation, pathogenesis, and management - Cain 2019 (VCNASP)
Middle-aged GSD (suspect genetic susceptibility) but other dogs can develop. Suspect immune-mediated. Long-term medical management now preferred to surgery (cyclosporine +/- ketoconazole > other immunosuppressants).
Evaluation of toceranib for treatment of AGASACA in dogs - Heaton 2020 (JVIM)
Retrospective (36 client-owned dogs with AGASACA +/- other chemo or surgery). Progression free survival ~ 313 d; overall survival time ~ 827 d. Benefit in ~ 69% with 20.7% partial responders + 48.3% stable disease (responders had significantly longer PFS + OST). Hypercalcemia negative prognostic indicator. Effective for AGASACA treatment in dogs.
Response and outcome following toceranib phosphate treatment for stage four AGASACA in dogs: 15 cases (2013-2017) - Elliott (JAVMA)
Retrospective (15 client-owned dogs with Palladia as sole agent). 13 dogs (87%) had clinical benefit but no complete or partial response. No SFX/toxicity requiring withdrawal. Median progression-free interval ~ 354 d; medial survival time ~ 356 d. Improved outcomes in stage 4 dogs compared to previously reported dogs not receiving TK inhibitors; not appropriate as sole treatment for dogs w/ significant CS attributable to AGASACA due to potential for euthanasia since CS did not always improve.
Efficacy of intravenous administration of apomorphine for removal of gastric foreign material in dogs: 495 cases (2010-2015) - Kirchofer 2019 (JAVMA)
Retrospective (495 dogs). Emesis in 363/495 after 1 dose (73%) + 11/495 (2%) after 2 doses - 374/495 (75%) total. More success - fabric, leather, bathroom waste, younger dogs, shorter time since ingestion. Less success - opioids, sedatives, antiemetics before administration. Minor SFX in 4 dogs (0.8%).
Aerodigestive disorders in dogs evaluated for cough using respiratory fluoroscopy and VFSS - Grobman 2019 (Vet Journal)
Retrospective (31 client-owned dogs with CXR + VFSS). Normal CXR 11/31 + AP 7/31. 25/31 (81%) had VFSS abnormalities - pharyngeal hypomotility (10/31 - 32%), esophageal hypomotility (10/31 - 32%), reflux (9/31 - 29%), P-A (8/31 - 26%), aerophagia (6/31 - 19%), laryngeal obstruction (3/31 - 10%), ME (3/31 - 10%), HH (2/31 - 6%), LES-AS (1/31 - 3%). Respiratory disorder (17/31 - 55%). Alimentary disorder WITHOUT respiratory disorder (8/31 - 26%).
Detection of silent reflux events by nuclear scintigraphy in healthy dogs - Grobman 2020 (JVIM)
Prospective (12 healthy client-owned dogs). 12/12 dogs (100%) had reflux of variable severity detected via NS. Median frequency - 2 events/5 minutes; median duration - 6 seconds. No dog had detectable aspiration.
Ultrasonographic features and prevalence of presumed gastric wall edema in dogs with hypoalbuminemia - Murakami 2020 (JVIM)
Retrospective - 42 dogs with Alb < 2.3. >5 mm considered thickened. Prevalence of thickening 21.4% with mean thickness ~ 10 mm. All 9 with thickening had submucosal thickening but preserved mucosa. All 9 also had peritoneal effusion. No correlation b/t Alb and thickness. Gastric wall thickening common in dogs with hypoalb. but levels did not correlate with thickness.
Ultrasonographic features of presumed gastric wall edema in 14 dogs with pancreatitis - Murakami 2019 (JVIM)
Retrospective - 14 dogs with acute panc. + gastric wall thickness > 5 mm. Mean thickness ~ 9.9 mm. Complete loss of layering in 2 dogs, thickened submucosa in 12 dogs, concurrent thickened muscularis in 5 dogs. Focal and adjacent to panc. in 12 dogs. Resolution observed in 3 dogs. Gastric wall thickening (suspect edema) could be complication of acute pancreatitis.
The effect of combined carprofen and omeprazole administration on gastrointestinal permeability and inflammation in dogs - Jones 2020 (JVIM)
6 healthy research beagles. LPS + plasma iohexol conc. did not differ b/t treatments. DI varied over time based on treatment received. Omeprazole + carprofen sig. inc. fecal calprotectin + DI compared to baseline and carprofen alone. Prophylactic omeprazole induces dysbiosis + inc. inflammatory markers when co-administered with carprofen.
Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats - Husnik 2020 (JVIM)
Prospective randomized double-blind crossover - 8 healthy DSH. Metoclopramide + erythromycin sig. sped up gastric emptying. Exenatide sig. slowed down emptying in first half of curve. Metoclopramide + erythromycin shorten gastric emptying times and inc. motiliy index of antral contractions; exenatide causes initial delay in gastric emptying.
The pattern of mortality in dogs with gastric dilatation and volvulus - Sharp 2020 (JVECC)
Retrospective - 498 dogs. 319 (64.1%) survived to discharge; 179 (35.9%) nonsurvivors - 149 nonsurvivors (31.3%) were euthanized [116/149 euthanized at presentation with no intent to treat] while 30 (6%) died. Excluding those euthanized at presentation, 83.5% survived to discharge. Euth. dogs older than survivors. Most mortality was pre-op. euthanasia w/o intent to treat - prevention will result in greater improvement in mortality than treatment.
Comparison of body condition score and other minimally invasive biomarkers between dogs with gastric carcinoma and dogs with chronic gastritis - Seim-Wikse 2019 (JAVMA)
Prospective - 15 carcinoma, 29 gastritis, 7 controls. Carcinoma - sig. older, lower BCS, lower folate, higher CRP. Age > 8 YO, BCS < 4, CRP > 25, hypofolatemia may be useful and should prompt biopsy.
Diagnostic evaluation of urea nitrogen/creatinine ratio in dogs with gastrointestinal bleeding - Stiller 2021 (JVIM)
Retrospective/prospective - 89 GIB (65 overt, 24 occult; 37 upper, 13 lower, 8 both) + 65 controls. UCR sig. higher in overt compared to occult and healthy; no diff. b/t upper and lower. Higher Hb/HCT lowered odds of occult GIB. Not clinically useful marker for occult + poorly discriminatory b/t upper + lower. Inc. UCR in dog w/o overt signs [esp. with normal HCT] does not warrant gastroprotectants.
Clinical characteristics of dogs with food-responsive protein-losing enteropathy - Nagata 2020 (JVIM)
Retrospective - 33 PLE. 23 dogs (70%) responded to ULFD. FRE had sig. lower CCECAI than IR/NRE (AUC of cutoff 8 - 0.935). MST sig. longer in FR (not reached) than IR/NR (432 days). FRE have favorable prognosis - CCECAI could help differentiate FR from IR/NRE.
Diagnostic value of fecal cultures in dogs with chronic diarrhea - Werner 2021 (JVIM)
Prospective case-control - 18 chronic diarrhea (CDG) + 18 controls. DI sig. inc. in CDG (0.9 vs -3.0) but culture failed to detect differences. Hemolytic E. coli only cultured enteropathogen, but no diff. b/t groups. No agreement b/t culture + DI, with high variability between culture laboratories. Fecal cultures failed to distinguish disease vs control and had high inter-laboratory variation.
Use of video capsule endoscopy to identify gastrointestinal lesions in dogs with microcytosis or gastrointestinal hemorrhage - Mabry 2019 (JVIM)
Retrospective case-conrol - 16 client-owned dogs with microcytosis, low-normal MCV, or clinical GIB with VCE. AUS (16), AXR (4), and CT (1) did not identify cause of GIB. 15/16 dogs had gastric mucosal lesions; 12/14 had SI mucosal lesions (2 capsules retained in stomach). 2 dogs scoped before VCE - 1 had additional SI lesions IDed. VCE is min. invasive + can help ID GI lesions in dogs w/ microcytosis or GIB when imaging inconclusive, however majority of lesions would have been apparent with endoscopy.
Association of chronic enteropathy activity index, blood urea concentration, and risk of death in dogs with protein-losing enteropathy - Kathrani 2019 (JVIM)
Retrospective - 71 client-owned PLE dogs. CCEAI + BUN sig. associated with death. For CCEAI, each unit increase inc. hazard by 22.9%. CCEAI < 8 survived 256 d longer; BUN < 7 survived 279 d longer. Inc. CCEAI + BUN at diagnosis might predict death in PLE (CE + lymphangiectasia).
Comparison of clinical, clinicopathologic, and histologic variables in dogs with chronic inflammatory enteropathy and low or normal serum 25-hydroxycholecalciferol concentrations - Wennogle 2019 (JVIM)
Prospective cohort - 15 CIE w/ low VD and 15 CIE w/ normal VD. Low-VD had higher CCECAI and CRP, and lower serum a-tocopherol, cholesterol, and Alb. VD-binding protein not diff. VD conc. neg. correlated w/ histopathologic changes. Path. likely multifactorial - consider fat malabsorption, but does not appear to be VDBP.
Ability of ultrasonography to predict the presence and location of histologic lesions in the small intestine of cats - Guttin 2019 (JVIM)
Retrospective - 169 cats. US changes had high PPV for histologic lesions (duo - 82%, jej - 91%, il - 88.1%). High PPV for mucosal lesions (72.7 - 100%) but low for submucosa or muscularis (18.9 - 57.1%). In pop. with high prevalence, SI mucosal US lesions will have histological lesions. Submucosal + muscularis US lesions not predictive of lesions in those layers so full-thickness biopsy may not be needed.
Differentiation of lymphocytic-plasmacytic enteropathy and small cell lymphoma in cats using histology-guided mass spectrometry - Marsilio 2020 (JVIM)
Retrospective - 41 LPE + 52 SCL. HGMS - Se 86.7%, Sp 91.7%, accuracy 88.9%. Clonality testing - Se 85.7%, Sp 33.3%, accuracy 61.5%. Diagnostic tests were compared to panel of pathologists. HGMS was reliable for diff. duodenal LPE + SCL and may have advantages over current tests.
Evaluation of novel serological markers and autoantibodies in dogs with inflammatory bowel disease - Estruch 2020 (JVIM)
Prospective control - 70 IBD, 23 non-IBD (acute) GI dx, 58 controls. IBD dogs 39 - 76% seropositivity against serologic markers; 0 - 13% in non-IBD and controls (ROC sig. different). OmpC highest single performance marker. OmpC - Se 76 - 97%, Sp 93 - 99%; APMNA - Se 66 - 86%, Sp 79 - 98%. IgA seropos. against markers appears promising to diff. IBD from other GI dx - E. coli OmpC + AAb against PMN had highest performance.
Association of fecal sample collection technique and treatment history with Tritrichomonas foetus polymerase chain reaction test results in 1717 cats - Hedgespeth 2020 (JVIM)
Retrospective (1808 fecal samples). 274 positives (16%). 2.04x OR of positivity for fecal loop via colonic flush. No correlation b/t results and treatment history or type (inc. prior ronidazole). 4/19 ronidazole-treated cats (21%) had second positive test. Fecal loop > colonic flush. Limitations to ronidazole - lack of association with PCR result + 21% failure rate.